Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 7;10(1):159–170. doi: 10.1016/j.apsb.2019.11.001

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 7 — Combination of biologic miR-328-3p with doxorubicin (DOX) or cisplatin (CPT) exhibits synergistic effects in the inhibition of osteosarcoma cell proliferation. (A) Cisplatin and (B) doxorubicin, alone or combined with miR-328-3p, exerted a dose-dependent response in the inhibition of MG63 and 143B cell viability, as determined by MTT assay at 48 h post-treatment. (C) The estimated EC₅₀ and Hill slop values for the antiproliferative activities of miR-328-3p, DOX and CPT. Values are mean ± SD (n = 4/group). (D) Chou-Talalay (CI-Fa) plots revealed a synergism for combined use of miR-328 and DOX or CPT in the control of human osteosarcoma cell proliferation.